The Latin America, Middle East and Africa Antibody Drug Conjugates Market is expected to witness market growth of 16.9% CAGR during the forecast period (2022-2028).
Antibody-drug conjugates are a novel therapeutic class that has piqued the interest of both large & small pharmaceutical companies. The cytotoxic medication's potency in an antibody-drug combination is 100-1000 times that of the cytotoxic drug acting alone. Despite the fact that this technology is present in the majority of multinational pharmaceutical corporations, only a few companies have the capability to develop ADC.
ADCs (antibody-drug conjugates) are complicated targeted medicines made up of a cytotoxic chemical attached to an antibody scaffold. The ADC is internalized by the tumor cell and processed by the endo-lysosomal pathway after interacting with the cell surface antigen recognized by the particular antibody. The linker between the payload and the antibody is subsequently severed, and the payload is released into the cytoplasm, where it uses its cytotoxic pathway to cause cell death. ADCs can also cause tumor cell death by the so-called bystander effect, which happens when the cytotoxic warhead diffuses throughout the cell membrane to neighboring cells, causing them to apoptosis.
The regional government is putting genuine efforts to strengthen the healthcare infrastructure and cure more cancer patients. The Brazzaville Declaration on Non-communicable Disease Prevention and Control in the WHO African Region, established in 2011, reiterated African countries' recognition of non-communicable diseases (NCDs), such as cancer, as a significant health threat. The signatories agreed, among other things, to create prevention efforts, fortify the health systems to lighten the stress of NCDs, raise funds to combat the diseases, and make the national health information systems more efficient in producing information on NCDs and their risk factors. Although, progress in this direction is still slow. Only 17 of the 46 countries in the African region that replied to a WHO survey in 2010 had strategies, operational cancer policies, or strategic plans. For instance, in 2018, the count was 752,000 new cancer cases (4 percent of the overall total) & 506,000 cancer deaths in Sub-Saharan Africa.
The Brazil market dominated the LAMEA Antibody Drug Conjugates Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $206.2 Million by 2028. The Argentina market is poised to grow at a CAGR of 17.5% during (2022 - 2028). Additionally, The UAE market is expected to display a CAGR of 16.6% during (2022 - 2028).
Based on Application, the market is segmented into Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others. Based on Technology, the market is segmented into Cleavable Linker, Non-Cleavable Linker, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline PLC, Pfizer, Inc., Astellas Pharma, Inc., Gilead Sciences, Inc., Seagen, Inc., ADC Therapeutics SA, and Daiichi Sankyo Company, Limited.
Antibody-drug conjugates are a novel therapeutic class that has piqued the interest of both large & small pharmaceutical companies. The cytotoxic medication's potency in an antibody-drug combination is 100-1000 times that of the cytotoxic drug acting alone. Despite the fact that this technology is present in the majority of multinational pharmaceutical corporations, only a few companies have the capability to develop ADC.
ADCs (antibody-drug conjugates) are complicated targeted medicines made up of a cytotoxic chemical attached to an antibody scaffold. The ADC is internalized by the tumor cell and processed by the endo-lysosomal pathway after interacting with the cell surface antigen recognized by the particular antibody. The linker between the payload and the antibody is subsequently severed, and the payload is released into the cytoplasm, where it uses its cytotoxic pathway to cause cell death. ADCs can also cause tumor cell death by the so-called bystander effect, which happens when the cytotoxic warhead diffuses throughout the cell membrane to neighboring cells, causing them to apoptosis.
The regional government is putting genuine efforts to strengthen the healthcare infrastructure and cure more cancer patients. The Brazzaville Declaration on Non-communicable Disease Prevention and Control in the WHO African Region, established in 2011, reiterated African countries' recognition of non-communicable diseases (NCDs), such as cancer, as a significant health threat. The signatories agreed, among other things, to create prevention efforts, fortify the health systems to lighten the stress of NCDs, raise funds to combat the diseases, and make the national health information systems more efficient in producing information on NCDs and their risk factors. Although, progress in this direction is still slow. Only 17 of the 46 countries in the African region that replied to a WHO survey in 2010 had strategies, operational cancer policies, or strategic plans. For instance, in 2018, the count was 752,000 new cancer cases (4 percent of the overall total) & 506,000 cancer deaths in Sub-Saharan Africa.
The Brazil market dominated the LAMEA Antibody Drug Conjugates Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $206.2 Million by 2028. The Argentina market is poised to grow at a CAGR of 17.5% during (2022 - 2028). Additionally, The UAE market is expected to display a CAGR of 16.6% during (2022 - 2028).
Based on Application, the market is segmented into Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others. Based on Technology, the market is segmented into Cleavable Linker, Non-Cleavable Linker, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline PLC, Pfizer, Inc., Astellas Pharma, Inc., Gilead Sciences, Inc., Seagen, Inc., ADC Therapeutics SA, and Daiichi Sankyo Company, Limited.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Breast Cancer
- Blood Cancer
- Urothelial Cancer & Bladder Cancer
- Others
By Technology
- Cleavable Linker
- Non-Cleavable Linker
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Takeda Pharmaceutical Company Limited
- F. Hoffmann-La Roche Ltd.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Pfizer, Inc.
- Astellas Pharma, Inc.
- Gilead Sciences, Inc.
- Seagen, Inc.
- ADC Therapeutics SA
- Daiichi Sankyo Company, Limited
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Antibody Drug Conjugates Market by Application
Chapter 5. LAMEA Antibody Drug Conjugates Market by Technology
Chapter 6. LAMEA Antibody Drug Conjugates Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Takeda Pharmaceutical Company Limited
- F. Hoffmann-La Roche Ltd.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Pfizer, Inc.
- Astellas Pharma, Inc.
- Gilead Sciences, Inc.
- Seagen, Inc.
- ADC Therapeutics SA
- Daiichi Sankyo Company, Limited
Methodology
LOADING...
